BioCentury | Jul 20, 2018
Company News

U of Helsinki grants Herantis rights to a non-invasive CDNF approach

...University of Helsinki (Helsinki, Finland) granted Herantis Pharma plc (HSE:HRTIS) exclusive, worldwide rights to a therapeutic approach for...
...looking "to broaden the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders." Herantis...
...suited for PD patients. University of Helsinki, Helsinki, Finland Herantis Pharma plc (HSE:HRTIS), Helsinki, Finland Business: Neurology Shannon Lehnbeuter Herantis Pharma plc University...
BioCentury | Apr 6, 2015
Clinical News

Cis-UCA Eye Drops: Completed Phase II enrollment

...placebo-controlled, U.S. Phase II trial evaluating 1% and 2.5% cis-UCA Eye Drops for 4 weeks. Herantis...
Items per page:
1 - 2 of 2
BioCentury | Jul 20, 2018
Company News

U of Helsinki grants Herantis rights to a non-invasive CDNF approach

...University of Helsinki (Helsinki, Finland) granted Herantis Pharma plc (HSE:HRTIS) exclusive, worldwide rights to a therapeutic approach for...
...looking "to broaden the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders." Herantis...
...suited for PD patients. University of Helsinki, Helsinki, Finland Herantis Pharma plc (HSE:HRTIS), Helsinki, Finland Business: Neurology Shannon Lehnbeuter Herantis Pharma plc University...
BioCentury | Apr 6, 2015
Clinical News

Cis-UCA Eye Drops: Completed Phase II enrollment

...placebo-controlled, U.S. Phase II trial evaluating 1% and 2.5% cis-UCA Eye Drops for 4 weeks. Herantis...
Items per page:
1 - 2 of 2